Introduction
============

Nasopharyngeal carcinoma (NPC) is the most common malignancy in the epithelial lining of the nasopharynx. NPC is unique in the aspects of epidemiology because of its prominent geographic distribution. The highest incidence rates of NPC are observed in the southern part of China, especially in Guangdong and Guangxi.[@b1-ott-10-909],[@b2-ott-10-909] Radiotherapy is used as a standard treatment for NPC because of the unique anatomical position and moderate radiosensitivity of the tumor. Despite the combined applications of magnetic resonance imaging (MRI), intensity-modulated radiation therapy (IMRT), chemotherapy, and targeted therapy, treatment for NPC still fails, especially when the tumor is in the advanced stage.[@b3-ott-10-909] Hence, prognostic predictors, such as gene single-nucleotide polymorphisms (SNPs), must be developed.

The *VEGF* gene is located in chromosome 6p12 and is composed of a 14 kb coding region with eight exons and seven introns. This gene plays a key role in the formation of new blood vessels.[@b4-ott-10-909] In this regard, the *VEGF* gene, as a major angiogenic factor, is thought to be associated with tumor development and metastasis; inhibition of vascular endothelial growth factor (VEGF) signaling can suppress tumor growth and angiogenesis by modulating the blood flow and oxygenation of the tumors.[@b5-ott-10-909] *VEGF* gene polymorphisms affect the aggressiveness and progression of NPC.[@b6-ott-10-909],[@b7-ott-10-909] However, the correlation of VEGF --460T/C gene polymorphism with the clinical outcomes in NPC has been rarely investigated. Our previous studies showed that VEGF --460T/C gene polymorphism is associated with the risk of NPC in the Chinese population.[@b8-ott-10-909],[@b9-ott-10-909] Thus, we carried out a retrospective study to assess the role of VEGF --460T/C gene polymorphism in the prognostic relevance by correlating it with the survival of NPC patients.

Materials and methods
=====================

Patients, treatment, and follow-up
----------------------------------

This study included 338 patients diagnosed with NPC at the First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi Province, People's Republic of China) between December 2012 and December 2013. The inclusion criteria were as follows: 1) the initial diagnosis of NPC was determined by pathologists according to World Health Organization (WHO) classification; 2) Karnofsky performance score (KPS) ≥90; 3) patients who underwent IMRT with platinum-based chemotherapy, along with regular follow-ups at our hospital; and 4) availability of peripheral blood samples. The exclusion criteria were as follows: 1) diagnosis with distant metastasis before treatment; 2) history of any other malignant disease; 3) any prior treatment for NPC; and 4) contraindications of radiotherapy. All the TNM classification was restaged according to the seventh edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) classification system. Written informed consents were obtained from all of the patients, and the research protocol was approved by the Ethical Review Committee of the First Affiliated Hospital of Guangxi Medical University. Information that can be used to identify individual participants during or after the data collection was available and can be accessed.

Each subject underwent the following pretreatment evaluations: patient history, physical examinations, hematological and biochemical profiling, chest radiography, abdominal sonography, MRI of the head and neck, and whole-body bone scan. The radiotherapy course was generally uniform. All the patients underwent definitive IMRT according to established methods.[@b10-ott-10-909] The patients also underwent two-to-three cycles of concurrent chemoradiotherapy (CCRT) and were administered cisplatin every 3 weeks. Neoadjuvant chemotherapy (NACT) was adopted in conjunction with CCRT in some patients. The NACT regimen comprised the administration of cisplatin with docetaxel every 3 weeks for two cycles. The chemotherapy was discontinued when the patient showed leukocyte counts lower than 3,000/mm^3^, or platelet count lower than 75,000/mm^3^. The chemotherapy was continued when the leukocyte and platelet counts reverted to the normal values.

The participants were followed up every 3 months during the first 2 years and then every 6 months thereafter, until the final follow-up or death of the participant. The follow-ups were conducted until February 2016. The median follow-up period was 31 months (range: 9--38 months). The overall survival (OS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) were selected as end points. OS was calculated from the date of enrollment to the date of the confirmed death (from any cause) or the last follow-up. LRFS was calculated from the date of enrollment to the date of the local recurrence or the last follow-up. DMFS was calculated from the date of enrollment to the date of the distant metastasis or the last follow-up. PFS was calculated from the date of enrollment to the date of any form of tumor progression or the last follow-up.

DNA extraction and genotyping
-----------------------------

Genomic DNA was extracted from peripheral blood (5 mL) at the time of enrollment for genotyping by using a commercially available kit according to the manufacturer's instructions (Tiangen Biotech, Beijing, Co, Ltd). The selected VEGF SNP (--460T/C) was genotyped through polymerase chain reaction (PCR) and direct DNA sequencing. The PCR primers used for the VEGF --460T/C were 5′-TGTGCAGACGGCAGTCACTA-3′ (upstream primer) and 5′-CCCGCTACCAGCCGACTTT-3′ (downstream primer). The PCR amplifications were performed in a 20 μL reaction volume containing 2 μL of genomic DNA, 0.6 μL of each primer, 10 μL of TaqMan Universal PCR Master Mix (Applied Biosystems), and 6.8 μL of DNA-free water. PCR was performed under the following conditions: initial denaturation at 94°C for 4 min, followed by 35 cycles of 30 s at 94°C, annealing at 62°C for 30 s, polymerization at 72°C for 45 s, and final holding at 72°C for 2 min. The PCR product was verified and genotyped through DNA sequencing. All the blood samples were genotyped successfully.

Statistical analysis
--------------------

Chi-square test was performed to determine the association between the SNP and the clinicopathological features of the patients. The odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were computed. Kaplan--Meier method was used to calculate the survival curves. The effect of the SNP on the clinical outcomes was assessed using the log-rank test. Multivariate analyses were then performed using a Cox proportional hazards model to calculate the hazard ratios (HRs) and the corresponding 95% CIs. All the statistical analyses were performed using the Statistical Product and Service Solutions software (SPSS; version 21.0). Two-sided *P*-values \<0.05 were considered statistically significant.

Results
=======

Patient characteristics
-----------------------

[Table 1](#t1-ott-10-909){ref-type="table"} shows the clinical characteristics of the 338 patients with NPC. The median age was 45 years (range: 13--76 years). IMRT combined with cisplatin-based chemotherapy was administered to all patients. A total of 139/338 (41.1%) patients received NACT. During the follow-up period, 25 patients were lost to follow-up. Twenty patients developed locoregional relapse, and 41 patients presented with distant metastasis. The 20 patients with locoregional relapse comprised 10 patients with nasal or nasopharyngeal relapse and 10 patients with relapse in the base of the skull. Forty-one patients with distant metastasis included 14 patients with pulmonary metastasis, 14 patients with hepatic metastasis, 9 patients with bone metastasis, and 4 patients with metastasis to multiple organs. At the end of the follow-up, 43 patients died from different causes. The following results were obtained: 3-year OS of 87.1%, 3-year LRFS of 93.7%, 3-year DMFS of 85.5%, and 3-year PFS of 80.5%.

Correlation of VEGF --460T/C polymorphism with the clinical features of the patients
------------------------------------------------------------------------------------

The genotyping results showed that the distribution of the VEGF --460C-allele genotypes among the 338 enrolled patients included 9.2% (31/338) CC, 37.9% (128/338) TC, and 52.9% (179/338) TT (homozygous wild allele). [Table 2](#t2-ott-10-909){ref-type="table"} summarizes the correlation of the VEGF --460T/C polymorphisms with the clinical features of the patients. The --460C-allele was significantly associated with high lymphatic metastasis, including N2--3 stage (OR =1.820, 95% CI: 1.118--2.962, *P*=0.015). However, this allele was not significantly associated with gender, age, clinical classifications, T classifications, distant metastasis, local recurrence, and disease progression (*P*\>0.05).

Associations of VEGF --460T/C gene polymorphisms with OS, LRFS, DMFS, and PFS of patients with NPC
--------------------------------------------------------------------------------------------------

Patients with VEGF --460T/T, VEGF --460T/C, and VEGF --460C/C genotypes showed 3-year OS of 95.1%, 76.7%, and 86.7%, respectively (*P*=0.008); and 3-year PFS of 86.7%, 70.8%, and 86.7%, respectively (*P*=0.047). Furthermore, the same patients had DMFS of 90.6%, 79.9%, and 81.7%, respectively (*P*=0.081); and LRFS of 92.8%, 95.1%, and 93.3%, respectively (*P*=0.862). The 3-year OS and PFS in patients with VEGF --460T/C and VEGF --460C/C genotypes were significantly lower than those of the patients with the VEGF --460T/T genotype. The outcomes are shown in [Figures 1](#f1-ott-10-909){ref-type="fig"}[](#f2-ott-10-909){ref-type="fig"}[](#f3-ott-10-909){ref-type="fig"}--[4](#f4-ott-10-909){ref-type="fig"}.

The combined effects of the genotypes on the survival of patients with NPC were assessed. The (T/C + C/C) genotype carriers had significantly lower 3-year OS, DMFS, and PFS compared with the wild-type T/T genotype carriers (95.1% vs 78.8%, *P*=0.003, [Figure 5](#f5-ott-10-909){ref-type="fig"}; 90.6% vs 80.2%, *P*=0.036, [Figure 6](#f6-ott-10-909){ref-type="fig"}; 86.7% vs 73.9%, *P*=0.042, [Figure 7](#f7-ott-10-909){ref-type="fig"}, respectively). In addition, LRFS was not significantly different between (T/C + C/C) and T/T genotype carriers ([Figure 8](#f8-ott-10-909){ref-type="fig"}).

Univariate and multivariate analyses for determining the prognostic factors of patients with NPC
------------------------------------------------------------------------------------------------

The univariate analysis indicated that the N classification was associated with OS, PFS, and DMFS (*P*=0.023, *P*=0.008, and *P*=0.014, respectively). Moreover, the VEGF --460 SNPs were significantly associated with OS (*P*=0.008) and PFS (*P*=0.047). Compared with the T/T genotype, the (T/C + C/C) genotype was associated with PFS (*P*=0.042), DMFS (*P*=0.036), and OS (*P*=0.003). The results are shown in [Tables 3](#t3-ott-10-909){ref-type="table"}[](#t4-ott-10-909){ref-type="table"}[](#t5-ott-10-909){ref-type="table"}--[6](#t6-ott-10-909){ref-type="table"}. Compared with patients receiving CCRT, the patients receiving NACT followed by CCRT had no signifi-cant improvement in their prognosis in terms of 3-year OS, LRFS, DMPS, and PFS in relation to the VEGF --460T/C polymorphism (*P*\>0.05; [Table 7](#t7-ott-10-909){ref-type="table"}).

The multivariate analysis results showed that the VEGF --460T/C polymorphism was an independent significant prognostic factor for OS (HR 4.096, 95% CI: 1.333--12.591, *P*=0.014). The N classification (N2--3 vs N0--1) was an independent significant prognostic factor for DMFS in patients with locoregionally advanced NPC (HR 3.674, 95% CI: 1.144--11.792, *P*=0.029). No significant association was observed between the predictors (gender, age, clinical classifications, T classifications, N classifications, chemotherapy regimens, and VEGF --460T/C SNP) and LRFS or PFS ([Table 8](#t8-ott-10-909){ref-type="table"}).

Discussion
==========

VEGF plays a pivotal role in prompting tumor angiogenesis, metastasis, and survival through a variety of mechanisms, such as the effects on endothelial cell proliferation, survival, and migration.[@b11-ott-10-909] Several VEGF SNPs were reported to be associated with variations in VEGF expression in vitro. Among these SNPs, the --460T/C polymorphism is related to high VEGF expression levels.[@b12-ott-10-909]--[@b14-ott-10-909] Our previous studies also revealed that the VEGF --460T/C gene polymorphism is associated with the risk of NPC and lymphatic metastasis in the Chinese population.[@b8-ott-10-909],[@b9-ott-10-909] Currently, the correlation between VEGF SNPs and NPC has been verified in a few studies. Wang et al[@b6-ott-10-909] demonstrated that patients with NPC harboring the --2578CC genotype exhibited increased aggressiveness, large size, poor differentiation, and advanced stage of tumors compared with patients harboring the --2578A-allele. Nasr et al[@b7-ott-10-909] found a significant association between the --2578C-allele carriers and aggressive forms of NPC, which were characterized by large tumors and advanced tumor stages. Furthermore, the VEGF SNPs influenced the prognosis and treatment toxicity in patients with different cancer types treated with CRT.[@b15-ott-10-909]--[@b18-ott-10-909] However, the association between VEGF --460T/C gene polymorphism and the clinical outcomes in NPC treated with IMRT has been rarely investigated.

In this study, a significant association was found between the --460C-allele carriers and aggressive forms of NPC, which were defined by the N2--3 stage (OR =1.820, 95% CI: 1.118--2.962, *P*=0.015). The VEGF --460T/C polymorphism was significantly associated with 3-year OS, 3-year DMFS, and 3-year PFS (T/C + C/C vs T/T: 3-year OS 78.8% vs 95.1%, *P*=0.003; 3-year DMFS 80.2% vs 90.6%, *P*=0.036; 3-year PFS 73.9% vs 86.7%, *P*=0.042) but was not associated with LRFS. The VEGF --460C-allele carrier (T/C + C/C) was an independent significant prognostic factor for the 3-year OS according to the multivariate analysis results (HR 4.096, 95% CI: 1.333--12.591, *P*=0.014). Our results might support the correlation between the polymorphisms in the VEGF --460T/C gene and poor clinical outcomes of NPC. Our results on the VEGF --460T/C SNP are consistent with the findings of previous studies on different cancer types. An in vitro study demonstrated that the VEGF --460T/C SNP is located in the promoter region and may play a role in the promoter activity. Thus, the VEGF --460C-allele may increase VEGF expression and thus may promote abnormal tumor angiogenesis and growth.[@b13-ott-10-909] High VEGF levels in the tumor microenvironment may cause rapid cancer progression and increased resistance of the tumors to radiotherapy and chemotherapy. Chen et al[@b12-ott-10-909] reported that patients with colorectal cancer harboring the VEGF --460T/C and VEGF --460C/C genotypes had significantly higher circulating VEGF levels, more aggressive tumor behavior, and lower chemotherapy sensitivity and prognosis than those with the wild-type T/T genotype; furthermore, the VEGF --460T/C gene polymorphisms were considered independent predictors of recurrence and prognosis in colorectal cancer. Masago et al[@b19-ott-10-909] also reported that the VEGF --460CC genotype had a negative prognostic effect on the survival of patients with advanced-stage non-small-cell lung cancer. Further, the survival rates of patients with NPC and overexpressed VEGF in tumor tissues were significantly lower than those of the patients with low VEGF expression.[@b20-ott-10-909] By contrast, Lv et al[@b21-ott-10-909] reported that elevated serum VEGF expression in patients with NPC was closely associated with DMFS and OS but was not significantly associated with LRFS. The correlation between VEGF and local recurrence of NPC after radiotherapy remains unclear. Radiotherapy could promote VEGF expression and enhance tumor angiogenesis, which may contribute to the radioresistance of NPC in mouse xenograft models. Therefore, radiotherapy combined with anti-VEGF therapy may effectively decrease radiation resistance.[@b22-ott-10-909] Our study also showed no significant association between LRFS and VEGF --460T/C polymorphism. This finding mainly stems from the following factors: first, despite more than 80% of the patients being at the T3--4 stage, the application of IMRT and combined CRT greatly improved the local control of the patients, resulting in 3-year LRFS of more than 90%. This effect might be a major reason that the VEGF SNP cannot attain significant effectiveness on LRFS. Second, we only focused on a single functional promoter VEGF SNP, and the results are not comprehensive. The result might have been influenced by the interference caused by the genetic linkages with other functional SNPs. Finally, we assumed that the VEGF --460T/C possessed some additional unknown biological functions. In summary, the VEGF --460T/C polymorphism may play a critical role in lymph node involvement, distant metastasis, and poor prognosis by promoting angiogenesis in NPC. The VEGF --460T/C polymorphism is thus a valuable prognostic marker for patients with NPC. However, the generalizability of our study is limited because we did not directly detect VEGF expression in tumor cells or evaluate the serum VEGF levels in the patients.

IMRT, which is widely used for patients with NPC, delivers a high radiation dose to tumors while maintaining a safe dose to normal tissues surrounding the tumor. This technique also exhibits excellent tumor coverage. Despite these advantages and the improved locoregional control with IMRT, patients are still at high risk of systemic failure and radioresistance.[@b10-ott-10-909] Thus, a combined modality therapy is necessary. In our study, the VEGF --460C-allele carrier (T/C + CC) was regarded as an inferior prognostic factor of survival according to IMRT. As such, we evaluated the influence of combining NACT with CCRT. Our results showed that the combination could not prolong 3-year OS, LRFS, DMFS, and PFS of the patients relative to those treated with CCRT alone. NACT did not improve the survival of the VEGF --460C-allele carriers in NPC, and the role of NACT remains unclear. Song et al[@b23-ott-10-909] also reported that the application of NACT followed by CCRT did not show superior effectiveness, compared with CCRT alone, in patients with NPC because NACT can increase the risk of locoregional recurrences. Qiu et al[@b24-ott-10-909] found that survival rates of patients treated with combined NACT and IMRT were not significantly different from those treated with CCRT plus adjuvant chemotherapy (AC). Meta-analysis results confirmed that integrating NACT to CCRT significantly improved PFS and OS, in contrast to CCRT with or without AC in locoregionally advanced NPC; however, an increased chance of developing acute toxicity, such as grade 3--4 anemia, thrombocytopenia, leukopenia, and fatigue, was observed.[@b25-ott-10-909] Recently, a combined radiotherapy and antiangiogenic therapy has been proposed and considered as a promising method for treatment of NPC. On the one hand, the proliferation and metastasis of tumor cells rely on angiogenesis induced by VEGF. On the other hand, rapidly growing tumors cause hypoxia, which upregulates VEGF, thereby promoting tumor proliferation, angiogenesis, and increased radioresistance. Thus, treatment that targets tumor angiogenesis can modulate the tumor microenvironment and thus can improve tumor blood flow and oxygenation, leading to enhanced radiosensitivity.[@b5-ott-10-909] Beva-cizumab, a recombinant humanized monoclonal antibody against VEGF, has progressed into clinical trials for different tumor types, and has a promising future.[@b26-ott-10-909]--[@b28-ott-10-909] Some studies also demonstrated that antiangiogenic therapy can normalize tumor vasculature and enhance radiation responses in xenografted human NPC models.[@b29-ott-10-909],[@b30-ott-10-909] The therapies that combine antiangiogenic therapy and radiotherapy might be promising strategies to inhibit angiogenesis and prevent adverse NPC outcomes. The result of our study must be viewed cautiously because of some limitations. Particularly, the number of participants was not sufficient, and the details of the underlying mechanisms were not investigated. Thus, our results must be validated and analyzed using larger sample sizes.

Conclusion
==========

This study demonstrated that the VEGF --460T/C polymorphism was associated with poor clinical outcomes in patients with NPC. The VEGF --460T/C polymorphism may be a potential prognostic indicator for patients with NPC and a promising target for treatment. Further studies must determine the effect of VEGF gene polymorphisms associated with combined modality therapy on NPC.
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###### 

Patient characteristics and clinical features

  Patient characteristics             Number (%)
  ----------------------------------- ------------
  Gender                              
   Male                               232 (68.6)
   Female                             106 (31.4)
  Age                                 
   ≤45 years                          174 (51.5)
   \>45 years                         164 (48.5)
  UICC/AJCC clinical classification   
   II                                 40 (11.8)
   III                                99 (29.3)
   IV                                 199 (58.9)
  T classification                    
   T2                                 60 (17.8)
   T3                                 83 (24.5)
   T4                                 195 (57.7)
  N classification                    
   N0                                 40 (11.8)
   N1                                 141 (41.7)
   N2                                 131 (38.8)
   N3                                 26 (7.7)
  Chemotherapy regimens               
   NACT + CCRT                        139 (41.1)
   CCRT alone                         199 (58.9)

**Abbreviations:** AJCC, American Joint Committee on Cancer; CCRT, concurrent chemoradiotherapy; NACT, neoadjuvant chemotherapy; UICC, International Union against Cancer.

###### 

Relationship of VEGF --460T/C genotype and allele with the clinical characteristics of the patients

  Characteristics           Genotype   T-allele   C-allele   OR    95% CI   *P*-value                  
  ------------------------- ---------- ---------- ---------- ----- -------- ----------- -------------- --------------------------------------------------
  Gender                                                                                               0.835
   Male                     122        87         23         331   133                                 
   Female                   56         41         9          153   59       0.946       0.561--1.595   
  Age, years                                                                                           0.259
   ≤45                      83         75         16         241   107                                 
   \>45                     95         54         15         244   84       0.756       0.465--1.229   
  Clinical classification                                                                              0.916
   II                       21         15         4          57    23                                  
   III--IV                  158        114        26         430   166      0.960       0.455--2.207   
  T classification                                                                                     0.446
   T1--2                    35         21         4          91    29                                  
   T3--4                    143        108        27         394   162      1.290       0.669--2.488   
  N classification                                                                                     0.015[\*](#tfn2-ott-10-909){ref-type="table-fn"}
   N0--1                    112        64         5          288   74                                  
   N2--3                    66         64         27         196   118      1.820       1.118--2.962   
  M classification                                                                                     0.077
   M0                       166        104        27         436   158                                 
   M1                       12         25         4          49    33       1.842       0.929--3.654   
  Local recurrence                                                                                     0.741
   Yes                      12         6          2          30    10                                  
   No                       166        122        30         454   182      1.192       0.420--3.379   
  Disease progression                                                                                  0.158
   Yes                      23         37         4          83    45                                  
   No                       156        91         27         403   145      0.656       0.365--1.181   

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** CI, confidence interval; OR, odds ratio; VEGF, vascular endothelial growth factor.

###### 

Univariate analysis of OS

  Variables               Cumulative survival   *P*-value              
  ----------------------- --------------------- ----------- ---------- --------------------------------------------------
  Gender                                                               
   Male                   97.3%                 87.9%       86.7%      0.872
   Female                 100.0%                87.9%       87.9%      
  Age, years                                                           
   ≤45                    98.8%                 86.7%       85.1%      0.515
   \>45                   97.5%                 89.3%       89.3%      
  Clinical stage                                                       
   II                     94.7%                 94.7%       94.7%      0.311
   III--IV                97.9%                 88.5%       86.0%      
  T classification                                                     
   T2                     100.0%                93.1%       93.1%      0.314
   T3--4                  97.7%                 86.7%       85.7%      
  N classification                                                     
   N0--1                  97.7%                 93.0%       93.0%      0.023[\*](#tfn4-ott-10-909){ref-type="table-fn"}
   N2--3                  98.6%                 81.8%       79.7%      
  Chemotherapy regimens                                                
   NACT + CCRT            100.0%                87.6%       87.6%      0.883
   CCRT                   96.9%                 88.2%       86.6%      
  --460T/C                                                             
   T/T                    98.8%                 95.1%       95.1%      0.008[\*](#tfn4-ott-10-909){ref-type="table-fn"}
   T/C                    96.8%                 78.9%       76.7%      
   C/C                    100.0%                86.7%       86.7%      
   T/T vs                 98.8% vs              95.1% vs    95.1% vs   0.003
   T/C + C/C              97.4%                 80.4%       78.8%      

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; OS, overall survival; NACT, neoadjuvant chemotherapy.

###### 

Univariate analysis of LRFS

  Variables               Cumulative survival   *P*-value              
  ----------------------- --------------------- ----------- ---------- -------
  Gender                                                               
   Male                   95.5%                 93.5%       93.5%      0.931
   Female                 94.1%                 94.1%       94.1%      
  Age, years                                                           
   ≤45                    96.4%                 93.9%       93.9%      0.891
   \>45                   93.5%                 93.5%       93.5%      
  Clinical stage                                                       
   II                     100.0%                100.0%      100.0%     0.238
   III--IV                94.4%                 92.8%       92.8%      
  T classification                                                     
   T2                     96.6%                 96.6%       96.6%      0.497
   T3--4                  94.7%                 93.0%       93.0%      
  N classification                                                     
   N0--1                  96.5%                 96.5%       96.5%      0.105
   N2--3                  93.2%                 90.2%       90.2%      
  Chemotherapy regimens                                                
   NACT + CCRT            97.0%                 90.6%       90.6%      0.212
   CCRT                   95.8%                 95.8%       95.8%      
  --460T/C                                                             
   T/T                    94.1%                 92.8%       92.8%      0.862
   T/C                    95.1%                 95.1%       95.1%      
   C/C                    100.0%                93.3%       93.3%      
   T/T vs                 94.1% vs              92.8% vs    92.8% vs   0.619
   T/C + C/C              96.1%                 94.7%       94.7%      

**Note:** *P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; LRFS, local recurrence-free survival; NACT, neoadjuvant chemotherapy.

###### 

Univariate analysis of DMFS

  Variables               Cumulative survival   *P*-value              
  ----------------------- --------------------- ----------- ---------- --------------------------------------------------
  Gender                                                               
   Male                   92.8%                 88.8%       84.5%      0.869
   Female                 92.2%                 90.0%       87.4%      
  Age, years                                                           
   ≤45                    91.7%                 87.6%       80.2%      0.223
   \>45                   93.7%                 90.9%       90.9%      
  Clinical stage                                                       
   II                     97.4%                 97.4%       85.3%      0.709
   III--IV                92.3%                 88.4%       85.8%      
  T classification                                                     
   T2                     93.1%                 93.1%       85.9%      0.677
   T3--4                  92.5%                 88.3%       85.5%      
  N classification                                                     
   N0--1                  94.4%                 94.4%       92.0%      0.014[\*](#tfn8-ott-10-909){ref-type="table-fn"}
   N2--3                  90.4%                 82.6%       77.0%      
  Chemotherapy regimens                                                
   NACT + CCRT            92.4%                 89.0%       84.3%      0.814
   CCRT                   92.8%                 89.4%       86.5%      
  --460T/C                                                             
   T/T                    95.3%                 95.3%       90.6%      0.081
   T/C                    88.7%                 79.9%       79.9%      
   C/C                    93.3%                 93.3%       81.7%      
   T/T vs                 95.3% vs              95.3% vs    90.6% vs   0.036[\*](#tfn8-ott-10-909){ref-type="table-fn"}
   T/C + C/C              89.6%                 82.5%       80.2%      

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; DMFS, distant metastasis-free survival; NACT, neoadjuvant chemotherapy.

###### 

Univariate analysis of PFS

  Variables               Cumulative survival   *P*-value              
  ----------------------- --------------------- ----------- ---------- ---------------------------------------------------
  Gender                                                               
   Male                   91.0%                 83.6%       79.8%      0.736
   Female                 90.2%                 82.0%       82.0%      
  Age, years                                                           
   ≤45                    89.8%                 81.7%       81.7%      0.816
   \>45                   90.5%                 79.4%       79.4%      
  Clinical stage                                                       
   II                     94.7%                 94.7%       94.7%      0.114
   III--IV                90.2%                 78.5%       78.5%      
  T classification                                                     
   T2                     89.7%                 89.7%       89.7%      0.196
   T3--4                  90.2%                 78.4%       78.4%      
  N classification                                                     
   N0--1                  92.2%                 88.7%       88.7%      0.008[\*](#tfn10-ott-10-909){ref-type="table-fn"}
   N2--3                  87.7%                 70.7%       70.7%      
  Chemotherapy regimens                                                
   NACT + CCRT            89.3%                 76.8%       76.8%      0.433
   CCRT                   88.6%                 83.1%       83.1%      
  --460T/C                                                             
   T/T                    93.7%                 86.7%       86.7%      0.047[\*](#tfn10-ott-10-909){ref-type="table-fn"}
   T/C                    85.5%                 70.8%       70.8%      
   C/C                    86.7%                 86.7%       86.7%      
   T/T vs                 93.7% vs              86.7% vs    86.7% vs   0.042[\*](#tfn10-ott-10-909){ref-type="table-fn"}
   T/C + C/C              85.7%                 73.9%       73.9%      

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; NACT, neoadjuvant chemotherapy; PFS, progression-free survival.

###### 

The 3-year OS, LRFS, DMFS, and PFS in the VEGF --460T/C genotype subgroups after chemotherapy regimens

  --460T/C genotype   3-year OS   *P*-value   3-year LRFS   *P*-value   3-year DMFS   *P*-value   3-year PFS   *P*-value                           
  ------------------- ----------- ----------- ------------- ----------- ------------- ----------- ------------ ----------- ------- ------- ------- -------
  T/T                 93.9%       95.9%       0.707         88.0%       96.1%         0.173       84.7%        96.2%       0.238   84.9%   87.9%   0.754
  T/C                 79.5%       74.6%       0.700         96.0%       94.7%         0.7815      81.8%        78.1%       0.587   63.3%   75.7%   0.420
  C/C                 85.7%       87.5%       0.881         85.7%       100.0%        0.285       85.7%        75.0%       0.962   85.7%   87.5%   0.922
  T/C + C/C           80.9%       80.0%       0.720         93.6%       95.6%         0.760       83.1%        76.8%       0.597   68.4%   77.8%   0.469

**Note:** *P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; DMFS, distant metastasis-free survival; LRFS, local recurrence-free survival; NACT, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; VEGF, vascular endothelial growth factor.

###### 

Multivariate analysis of OS, DMFS, LRFS, and PFS

  Variables                                      HR      95% CI          *P*-value
  ---------------------------------------------- ------- --------------- ---------------------------------------------------
  Results of the multivariate analysis of OS                             
   Gender (female vs male)                       1.149   0.412--3.205    0.790
   Age (\>45 vs ≤45 years)                       0.967   0.379--2.466    0.944
   T classification (T3--4 vs T2)                1.671   0.203--13.786   0.633
   N classification (N2--3 vs N0--1)             2.490   0.840--7.377    0.100
   Chemotherapy (CCRT vs NACT + CCRT)            1.169   0.450--3.036    0.749
   VEGF --460T/C SNP (T/C + C/C vs T/T)          4.096   1.333--12.591   0.014[\*](#tfn14-ott-10-909){ref-type="table-fn"}
  Results of the multivariate analysis of DMFS                           
   Gender (female vs male)                       1.169   0.422--3.241    0.764
   Age (\>45 vs ≤45 years)                       0.667   0.254--1.747    0.409
   T classification (T3--4 vs T2)                1.906   0.232--15.688   0.549
   N classification (N2--3 vs N0--1)             3.674   1.144--11.792   0.029[\*](#tfn14-ott-10-909){ref-type="table-fn"}
   Chemotherapy (CCRT vs NACT + CCRT)            1.004   0.390--2.585    0.994
   VEGF --460T/C SNP (T/C + C/C vs T/T)          2.442   0.913--6.531    0.075
  Results of the multivariate analysis of LRFS                           
   Gender (female vs male)                       0.848   0.203--3.543    0.821
   Age (\>45 vs ≤45 years)                       1.338   0.367--4.872    0.659
   T classification (T3--4 vs T2)                0.892   0.096--8.257    0.920
   N classification (N2--3 vs N0--1)             2.449   0.600--10.002   0.212
   Chemotherapy (CCRT vs NACT + CCRT)            0.434   0.114--1.654    0.222
   VEGF --460T/C SNP (T/C + C/C vs T/T)          0.708   0.185--2.713    0.614
  Results of the multivariate analysis of PFS                            
   Gender (female vs male)                       0.922   0.404--2.101    0.846
   Age (\>45 vs ≤45 years)                       1.210   0.581--2.518    0.610
   T classification (T3--4 vs T2)                1.152   0.253--5.238    0.855
   N classification (N2--3 vs N0--1)             2.189   0.967--4.956    0.060
   Chemotherapy (CCRT vs NACT + CCRT)            0.763   0.360--1.616    0.480
   VEGF --460T/C SNP (T/C + C/C vs T/T)          2.023   0.937--4.368    0.073

**Note:**

*P*\<0.05 was considered statistically significant.

**Abbreviations:** CCRT, concurrent chemoradiotherapy; CI, confidence interval; DMFS, distant metastasis-free survival; HR, hazard ratio; LRFS, local recurrence-free survival; NACT, neoadjuvant chemotherapy; OS, overall survival; PFS, progression-free survival; SNP, single-nucleotide polymorphism; VEGF, vascular endothelial growth factor.
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